Shares of Aeluma surged 11% to $18.50 in pre-market trading Thursday, extending a blistering 30% rally from $14.19 over the past week. The catalyst: on July 29, Aeluma signed a Letter of Intent for up to $30 million in CHIPS Act funding to develop its photonics semiconductor platform. Investors are treating the news as a transformative moment. The math tells a more nuanced story.
$30 Million Is Enormous Relative to This Company's Size — But It's Not a Done Deal. Aeluma's trailing twelve-month revenue stands at just $5.2 million, with a net loss of $6 million. A $30 million R&D award would represent nearly six years of current revenue. But the award is contingent on due diligence, approvals — including from the Secretary of Commerce — and definitive documentation.
Equity issuance to the Commerce Department equal to the award amount implies dilution — meaning the government would receive newly issued Aeluma shares, shrinking existing investors' ownership stakes.
The Revenue Picture Hasn't Kept Up with the Stock Price. Q3 fiscal 2026 revenue came in at $1.22 million, missing analyst estimates of $1.38 million by roughly 12%.
Management narrowed full-year guidance to $4.2–$4.6 million, down from an earlier $4.0–$6.0 million range , citing government contract delays. The stock trades at a price-to-sales ratio above 52x trailing revenue — a premium that bakes in years of growth that hasn't materialized yet.
The AI Photonics Angle Is Real, but Commercial Proof Is Missing. Aeluma's platform builds high-performance photonic chips on large wafers up to 300mm — an alternative to traditional materials that are harder to scale. That matters because AI data centers are hungry for faster optical connections. However, no major manufacturer contract has been secured yet, and shares outstanding rose 37% last year to fund operations. Cash stands at $37.8 million , giving the company roughly two years of runway at current burn rates — adequate, but not generous for a pre-commercialization firm.
The Bottom Line for Shareholders. The CHIPS Act letter validates Aeluma's technology in Washington's eyes and could fund its path toward commercial-scale production. But the stock now implies a market value approaching $340 million on sub-$5 million revenue, no profits, and an award that remains proposed. The gap between government endorsement and paying customers is where the real risk — and the real opportunity — lives.